New shigella vaccine shows promise in first human trials
NCT ID NCT05073003
First seen Jan 04, 2026 · Last updated May 07, 2026 · Updated 23 times
Summary
This study tested a new vaccine designed to protect against Shigella bacteria, a major cause of diarrhoea in children. Researchers gave the vaccine to 551 healthy people in Europe and Africa, including adults, children, and infants. The goal was to check safety and see how well the immune system responds, with the aim of finding the best dose for infants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Kericho, 20200, Kenya
Conditions
Explore the condition pages connected to this study.